Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial

Context: Male hormonal contraception (MHC) combines hypothalamic-pituitary-gonadal axis blockade with exogenous androgen delivery to maintain extragonadal androgen end-organ effects. Concern exists that MHC may adversely impact prostate health. Objective: The objective of the study was to determine the molecular impact of MHC on intraprostatic androgen concentrations and androgen action. Design: This was a single-blind, randomized, placebo-controlled study. Setting: The study was conducted at an academic medical center. Participants: 32 healthy men aged 25-55 yr participated in the study. Intervention: Interventions included placebo, daily transdermal testosterone (T) (T-gel), T-gel + depomedroxyprogesterone acetate (T+DMPA), or T-gel + dutasteride daily (T+D) for 12 wk, and prostate biopsy during treatment wk 10. Main Outcome Measures: Serum and prostate androgen concentrations and prostate epithelial-cell gene expression were measured. Results: Thirty men completed the study. Serum T levels were significantly increased in T-gel and T+D groups compared with baseline (P < 0.05) but were decreased with the addition of DMPA. Intraprostatic androgens were no different from placebo with T-gel treatment. Addition of DMPA to T resulted in 40% lower intraprostatic dihydrotestosterone (DHT) concentration (P = 0.0273 vs. placebo), whereas combining dutasteride with T resulted in a 90% decrease in intraprostatic DHT (P = 0.0012), 11-fold increased intraprostatic T (P = 0.0011), and 7-fold increased intraprostatic androstenedione (P = 0.0011). Significant differences in global or androgen-regulated prostate epithelial-cell gene expression were not observed. Androgen-regulated gene expression correlated with epithelial-cell androgen receptor and prostatic DHT in placebo, T-gel, and T+DMPA arms and with T and androstenedione levels in the T+D arm. Conclusions: MHC regimens do not markedly alter gene expression in benign prostate epithelium, suggesting they may not alter risk of prostate disease. Longer-term studies examining the impact of MHC on prostate health are needed.     

Association of serum retinol-binding protein 4 with insulin resistance and metabolic parameters during olanzapine therapy

Objective Retinol‐binding protein 4 (RBP4) has been shown to be associated with insulin resistance (IR), metabolic indices and metabolic syndrome (MetS) in various patient populations and in obesity. We investigated the association between metabolic parameters, IR and RBP4 during olanzapine therapy. Design A prospective study. Patients Thirty‐seven participants with psychiatric disorder who were atypical antipsychotic naive and newly initiated on olanzapine were assessed. Measurements Fasting RBP4, anthropometric and metabolic variables were measured before and after 3 months of olanzapine therapy. Results Participants who developed MetS showed higher RBP4 levels compared with those without MetS, although not significant (P = 0·053). The variation in RBP4 level was correlated with changes in systolic blood pressure (r = 0·423, P = 0·009), diastolic blood pressure (r = 0·390, P = 0·017), total cholesterol (r = 0·446, P = 0·006) and low‐density lipoprotein (LDL) (r = 0·407, P = 0·012). Multiple linear regression analysis illustrated that end‐point log insulin level was the most significant independent predictor of final log RBP4 levels (standardized ß = 0·353, P = 0·024). Conclusions Our results suggest that RBP4 levels might be associated with at least some olanzapine‐induced metabolic abnormalities and cardiovascular disease risk factors.     

Effects of self-controlled feedback on learning of a throwing task in children with spastic hemiplegic cerebral palsy

The purpose of this study was to examine the effect of self-controlled feedback on learning a throwing task in children with spastic hemiplegic cerebral palsy (SHCP). In order to achieve the research objectives, using a semi-experimental method, 20 children with SHCP (7–12 years old) were selected from special schools in Tehran, Iran. After showing the participants how to do the throwing task, a pre-test with 10 trials was conducted to homogenize the participants. Then, they were randomly assigned to two groups (self-control group and yoked group) to be examined in acquisition, retention, and transfer phases. Children in self-control group requested feedback when necessary during the acquisition phase. In contrast, participants in yoked-group replicated the feedback schedules of their counterparts in self-control group without any choice. A multivariate analysis of variance (MANOVA) was performed to analyze the data. Based on the results, a significant difference was not found between the self-control and yoked-group in acquisition phase (F = .538, p < .473). However, there was a significant difference between the two groups in retention (F = 11.72, p < .003) and transfer (F = 6.74, p < .018) phases. Thus, based on the better results obtained in the self-control condition, this type of feedback can be used in physiotherapy programs related to children with CP to improve their motor skills and independence movements.     

Nanoporous MIL-101(Cr) as a sensing layer coated on a quartz crystal microbalance (QCM) nanosensor to detect volatile organic compounds (VOCs)

The application of metal–organic frameworks (MOFs) as a sensing layer has been attracting great interest over the last decade, due to their high porosity and tunability, which provides a large surface area and active sites for trapping or binding target molecules. MIL-101(Cr) is selected as a good candidate from the MOFs family to fabricate a quartz crystal microbalance (QCM) nanosensor for the detection of volatile organic compound (VOC) vapors. The structural and chemical properties of synthesized MIL-101(Cr) are investigated by X-ray diffraction (XRD), Fourier-transfer infrared spectroscopy (FTIR) and scanning electron microscopy (SEM) and so on. A stable and uniform layer of MOF is coated onto the surface of a QCM sensor by the drop casting method. The frequency of the QCM crystal is changed during exposure to different concentrations of target gas molecules. Here, the sensor response to some VOCs with different functional groups and polarities, such as methanol, ethanol, isopropanol, n-hexane, acetone, dichloromethane, chloroform, tetrahydrofuran (THF), and pyridine under N₂ atmosphere at ambient conditions is studied. Sensing properties such as sensitivity, reversibility, stability, response time, recovery time, and limit of detection (LOD) of the sensor are investigated. The best sensor response is observed for pyridine detection with sensitivity of 2.793 Hz ppm⁻¹. The sensor shows short response/recovery time (less than two minutes), complete reversibility and repeatability which are attributed to the physisorption of the gases into the MOF pores and high stability of the device.

Metal–organic frameworks can be used as sensing layer in QCM fabrication because of their huge surface area.     

Repeat expansion in C9ORF72 is not a major cause of amyotrophic lateral sclerosis among Iranian patients

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in populations of European descent. It was recently found that a hexanucleotide repeat expansion in C9ORF72 is its most common cause in these populations. The contribution of C9ORF72 to ALS is notably lower in the Far East, but its role in other populations is unknown. Results of C9ORF72 screening in 78 unrelated Iranian ALS patients are reported here. The repeat expansion was observed in only 1 (5.9%) of the familial and 1 (1.6%) of the sporadic cases. These figures are to be compared, respectively, with 30% and 6.9% among patients of European ethnicity. Screenings of C9ORF72 in other Middle East countries will reveal whether the low contribution of C9ORF72 to ALS is a feature of the entire region. During the screenings, it was noted that in a single family, 3 individuals affected with ALS, Parkinson's disease, or frontotemporal dementia all carried the repeat expansion. The finding suggests the mutation does rarely contribute to the etiology of Parkinson's disease.     

A rare case report: SCARF syndrome

SCARF syndrome is a very rare syndrome that so far only two cases have been reported in the papers. In this article, a 3‐month‐old female who exhibited SCARF syndrome presented with multiple congenital abnormalities and problems at Imam Hossein hospital of Shahroud.     

Fibroblast Growth Factor Type 1 (FGF1)-Overexpressed Adipose-Derived Mesenchaymal Stem Cells (AD-MSC<Superscript>FGF1</Superscript>) Induce Neuroprotection and Functional Recovery in a Rat Stroke Model

Stroke, as the second most common cause of death, imposes a great financial burden on both the individual and society. Mesenchymal stem cells from rodents have demonstrated efficacy in experimental animal models of stroke due to enhanced neurological recovery. Since FGF1 (fibroblast growth factor 1) displays neuroprotective properties, for the first time, we investigated the effect of acute intravenous administration of FGF1 gene transfected adipose-derived mesenchymal stem cell (AD-MSC^FGF1) on transient experimental ischemic stroke in rats. Stroke induction was made by transient middle cerebral artery occlusion (tMCAO). 2?×?10⁶ AD-MSC^FGF1 was administrated intravenously 30 min after carotid reperfusion. The ability of technetium^99m-hexamethyl propylene amine oxime (^99mTc-HMPAO)-labeled AD-MSC^FGF1 to enter into ischemic brain was evaluated 2 h post injection. 24 h post operation, the neurological recovery (rotarod and Roger’s tests), the infarct volume (2, 3, 5-triphenyltetrazolium chloride, TTC assay), apoptosis rate (TUNEL assay), and the expression of FGF1 protein (western blotting) in the ischemic hemisphere were assessed. The ^99mTc-HMPAO-labeled AD-MSC^FGF1 could enter into the ischemic brain. Ischemic hemisphere activity was significantly higher than that observed in the contralateral hemisphere (p?=?0.002). The administration of AD-MSC^FGF1 resulted in significant improvement of neurological function tests and increased density of FGF1 protein in the peri-infarct area, while the infarct volume and the apoptotic index were significantly decreased, in comparison to the other treated groups. In conclusion, acute intravenous administration of AD-MSC^FGF1 can be a novel and promising candidate approach for the treatment of ischemic stroke.